[Conformal radiotherapy for prostate cancer].
Data are presented on a retrospective comparison of the results of remote radiotherapy and combined treatment of prostate cancer (T2T4NxM0) (88) at the Center's Clinics (1999-2003). Diagnosis was confirmed by morphological evidence: T2NxM0 (group 1)--18.2%, T3aNx M0 (group 2)--53.4%, T3bNx M0 (group 3)--18.2%, T4NxM0--10.2% (group 4). In group 1 (n=37), contemporary radiotherapy was administered--TTD--up to 44 Gy (stage I) and up to 66-70 Gy (stage II). In group 2 (n=51), contemporary radiotherapy was supplemented with inhalation of radioprotector GGS-9--TTD--up to 44 Gy plus GGS-9 (stage I) and up to 72-76 Gy plus conformaton radiotherapy (3D CRT) (stage II). When GGS-9 was used at stage I the rate of acute radiation injury dropped from 56.7% in group 1 to 11.7% in group 2, (p=0.0001). The frequency of late-onset injury was also lower in patients receiving 3D CRT (13.5 and 3.9%, respectively) (p=0.01). Local and biological relapse occurred frequently after contemporary radiotherapy (27%) as compared with conformation one (5.8%). The latter treatment was followed by higher 5-year recurrence-free survival (94.2%) as compared with contemporary radiotherapy (73%), (p=0.0001). Owing to use of 3D CRT, dose distribution was improved as volume and dosage for organs at risk of irradiation decreased, while TTD increased up to 72-76 Gy unaccompanied by a rise in early-onset injuries. On the contrary, late-onset radiation damage fell down.
Tkachev
S I
SI
Matveev
V B
VB
Trofimova
O P
OP
Nazarenko
A V
AV
Pylova
I V
IV
Priamikova
Iu I
IuI
D000368:Aged; D000369:Aged, 80 and over; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage; D014408:Biomarkers, Tumor / Q000097:blood; D017024:Chemotherapy, Adjuvant; D004307:Dose-Response Relationship, Radiation; D004334:Drug Administration Schedule; D006801:Humans; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy / Q000379:methods; D009367:Neoplasm Staging; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000276:immunology / Q000473:pathology / Q000532:radiotherapy*; D011879:Radiotherapy Dosage; D011880:Radiotherapy Planning, Computer-Assisted; D020266:Radiotherapy, Conformal; D050397:Radiotherapy, Intensity-Modulated; D016896:Treatment Outcome
D018931:Antineoplastic Agents, Hormonal; D014408:Biomarkers, Tumor; D017430:Prostate-Specific Antigen